ACADIA Pharmaceuticals Inc. (ACAD), Alnylam Pharmaceuticals, Inc. (ALNY) & Celldex Therapeutics, Inc. (CLDX): Buy These Biotech Companies for Long-Term Growth

AALN-TTR02 has shown a 93% reduction in wild-type and mutant transthyretin, or TTR, genes. TTR genes cause abnormal amyloid proteins that damage organs and tissue, which can result in death. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will initiate the phase three trial by the end of this year, and this drug might receive approval by next year, or by 2015, in the U.S. There are around 50,000 patients globally suffering from various kinds of ATTR. Therefore, this will generate revenue of around $4.6 million in 2016 and reach $57.4 million in 2017.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is also developing ALN-AT3 for the treatment of hemophilia and rare bleeding disorders. Patients suffering from hemophilia bleed for longer time than normal. The company plans to initiate phase one testing of ALN-AT3. Results from animal testing are promising, as it has reduced Antithrombin levels. Antithrombin is a protein that inactivates enzymes responsible for blood coagulation. A six week dosage was given to animals and showed positive results. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will file an investigational new drug application this year, and phase one will begin. Hemophilia is a hereditary disorder, and there are around 40,000 patients in the U.S. and European Union. This drug will access the global hemophilia market, which will grow from $8.9 billion last year to $11.4 billion by 2016, up by a Combined Annual Growth Rate (CAGR) of 5.9%.

Bottom line for investors

All these companies have a few drugs in the pipeline, which provide a promising future. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s new drug Pimavanserin has huge potential in ADP and PDP treatment. Positive results from clinical testing will boost investors’ confidence in this stock.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is focusing on treating both breast cancer and brain cancer, as it is moving ahead with new drugs Conjugate and Rindopepimut.

ALN-TTR02 drug could be a game-changer for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), and ALN-AT3’s future growth prospects are sound.

I will recommend buying these three stocks for long-term growth.

The article Buy These Biotech Companies for Long-Term Growth originally appeared on Fool.com.

Madhu is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.